Dominance in Dialysis Digs DaVita a Moat

DaVita's DVA narrow economic moat is due to the company's dominant and essential position in the U.S. dialysis market, accounting for over one third of all dialysis facilities and patient treatments. DaVita provides lifesaving healthcare services to chronically ill patients in a low-cost, outpatient setting. Because the alternative to outpatient dialysis is higher-cost, less-efficient, and more-burdensome acute therapy, we see little likelihood of DaVita faltering due to regulatory disruption in the long term.